SCHEMBL1663459

SCHEMBL1663459

CC(C)c1nc2cc(O)ccc2c(=O)n1-c1ccc(Cl)cc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.54
ESR1 P03372 3/20 0.44
ESR2 Q92731 2/20 0.44
GLA P06280 2/20 0.42
APAF1 O14727 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
EGFR P00533 2/20 0.39
SLC22A12 Q96S37 1/20 0.39
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
POLB P06746 1/20 0.38
PLK4 O00444 1/20 0.37
AURKA O14965 1/20 0.37
PDPK1 O15530 1/20 0.37
ROCK2 O75116 1/20 0.37
PRKCG P05129 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663987 0.85 TRPV1 (0.53) TRPV1ESR1ESR2GLAL3MBTL1
SCHEMBL1663398 0.82 TRPV1 (0.72) TRPV1ESR1ESR2KMT2AKDM4E
SCHEMBL1664029 0.80 TRPV1 (0.62) TRPV1ESR1ESR2MAPTKDM4E
SCHEMBL1664030 0.78 TRPV1 (0.57) TRPV1ESR1ESR2GLAKMT2A
SCHEMBL14396514 0.77 TRPV1 (0.62) TRPV1ESR1ESR2L3MBTL1KMT2A
SCHEMBL10446158 0.77 TRPV1 (0.72) TRPV1ESR1ESR2MAPTKDM4E
SCHEMBL10446219 0.77 TRPV1 (0.71) TRPV1ESR1ESR2MAPTKDM4E
SCHEMBL1663525 0.77 TRPV1 (0.51) TRPV1ESR1ESR2EGFRKMT2A
SCHEMBL10446210 0.76 TRPV1 (0.64) TRPV1ESR1ESR2GLAKMT2A
SCHEMBL1662144 0.76 TRPV1 (0.52) TRPV1ESR1ESR2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
CN-101356160-A Trisubstituted quinazolinone derivatives as vanilloid antagonists JANSSEN PHARMACEUTICA NV (CH) 2009-01-28 CN disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885ESR1 1321/4885ESR2 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.